Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10806930 | 0.84 | KIF11 (0.52) | MAPK1MAPTKMT2AALDH1A1TAAR1 | |
| SCHEMBL240161 | 0.81 | MAPK1 (0.50) | MAPK1MAPTKMT2ACYP2C19HIF1A | |
| SCHEMBL9669699 | 0.81 | MAPK1 (0.50) | MAPK1MAPTKMT2ACYP2C19HIF1A | |
| SCHEMBL17078011 | 0.77 | ALDH1A1 (0.52) | MAPK1MAPTKMT2ACYP2C19HIF1A | |
| SCHEMBL8607709 | 0.77 | MAPT (0.50) | MAPK1MAPTKMT2ACYP2C19HIF1A | |
| SCHEMBL7647641 | 0.77 | TSHR (0.52) | MAPK1MAPTKMT2ACYP2C19HIF1A | |
| SCHEMBL927239 | 0.75 | MAPK1 (0.50) | MAPK1MAPTKMT2ACYP2C19HIF1A | |
| SCHEMBL6850 | 0.75 | MAPK1 (0.50) | MAPK1MAPTKMT2ACYP2C19HIF1A | |
| SCHEMBL18127935 | 0.75 | MAPK1 (0.50) | MAPK1MAPTKMT2ACYP2C19HIF1A | |
| SCHEMBL6573475 | 0.75 | MAPK1 (0.44) | MAPK1MAPTKMT2ACYP2C19HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 794 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196225-A1 | Photo Patternable Coating Compositions of Silicones and Organic-Inorganic Hybrids | NAMITEK SPECIALTY MATERIALS CORP. (US) | 2012-08-02 | — | — | US | claimed |
| US-7842744-B2 | excellent in ultraviolet absorption capability at 380 nm with little bleed-out; resin and an absorber, which is a tris/2-hydroxyphenyl/ triazine compound | ADEKA CORPORATION (JP) | 2010-11-30 | — | — | US | claimed |
| EP-1734038-B1 | NITROGENOUS HETEROCYCLE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT EMPLOYING THE SAME | IDEMITSU KOSAN CO (JP) | 2009-11-04 | — | — | EP | claimed |
| US-20090258976-A1 | excellent in ultraviolet absorption capability at 380 nm with little bleed-out; resin and an absorber, which is a tris/2-hydroxyphenyl/ triazine compound | NEGISHI YOSHINORI | 2009-10-15 | — | — | US | claimed |
| US-7553892-B2 | excellent in ultraviolet absorption capability at 380 nm with little bleed-out; resin and an absorber, which is a tris/2-hydroxyphenyl/ triazine compound | ADEKA CORPORATION (JP) | 2009-06-30 | — | — | US | claimed |
| US-20050027008-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredient | TEIJIN LIMITED | 2005-02-03 | — | — | US | claimed |
| EP-1063235-B1 | BENZOFURYLPYRONE DERIVATIVES | TEIJIN LTD (JP) | 2004-05-12 | — | — | EP | claimed |
| US-20030191306-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-10-09 | — | — | US | claimed |
| US-20030186976-A1 | Benzofurylpyrone derivatives | TEIJIN LIMITED, MICROBIAL CHEMISTRY RESEARCH FOUNDATION | 2003-10-02 | — | — | US | claimed |
| US-6589984-B1 | Blood cholesterol and triglycerides (TG) themselves are generally insoluble in blood, and they exist as lipoproteins by binding with apolipoproteins. In the body, triglycerides are biosynthesized primarily in the liver from acetyl CoA as | TEIJIN LIMITED (JP) | 2003-07-08 | — | — | US | claimed |
| EP-1292579-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | Pharmacia Corporation (US) | 2003-03-19 | — | — | EP | claimed |
| US-20020198199-A1 | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2002-12-26 | — | — | US | claimed |
| WO-2001087854-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-11-22 | — | — | WO | claimed |
| WO-2001087852-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL URACILS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-11-22 | — | — | WO | claimed |
| JP-3187838-B2 | — | — | 2001-07-16 | — | — | JP | claimed |
| EP-1063235-A1 | BENZOFURYLPYRONE DERIVATIVES | TEIJIN LIMITED (JP) | 2000-12-27 | — | — | EP | claimed |
| EP-0737195-A1 | NEW GINKGOLIDE DERIVATIVES AND A PROCESS FOR PREPARING THEM | SUNKYONG INDUSTRIES CO., LTD. (KR) | 1996-10-16 | — | — | EP | claimed |
| US-5541183-A | RESPIRATORY SYSTEM DISORDERS, SKIN DISORDERS AND PLATELET ACTIVATING FACTOR ANTAGONIST | SUNKYONG INDUSTRIES CO., LTD. (KR) | 1996-07-30 | — | — | US | claimed |
| WO-1995018131-A1 | NEW GINKGOLIDE DERIVATIVES AND A PROCESS FOR PREPARING THEM | SUNKYONG INDUSTRIES CO., LTD. (KR) | 1995-07-06 | — | — | WO | claimed |
| US-4647579-A | Circulation active novel substituted 4-hydroxy-benzopyrans | BAYER AKTIENGESELLSCHAFT (DE) | 1987-03-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191306-A1 | Substituted N-Aliphatic-N-Aromatictertiary-Heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, MTTP | MAPK1 3625/4885MAPT 1679/4885KMT2A 3677/4885 |
| US-20020198199-A1 | Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade | TFPI, F2, PLAT | MAPK1 1628/4885MAPT 4843/4885KMT2A 3534/4885 |
| US-20030186976-A1 | Benzofurylpyrone derivatives | PLIN5, ACSL5, PLIN1 | MAPK1 1370/4885MAPT 3955/4885KMT2A 4009/4885 |
| US-20050027008-A1 | Cancer remedy comprising anthranilic acid derivatives as active ingredient | CA9, HCCS, CA7 | MAPK1 2551/4885MAPT 4853/4885KMT2A 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.